Journal
THERAPEUTIC ADVANCES IN DRUG SAFETY
Volume 2, Issue 1, Pages 19-28Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2042098610393209
Keywords
coronary artery disease; drug safety; I-f channel; I-f channel inhibitor; ivabradine
Categories
Ask authors/readers for more resources
Ivabradine is a new bradycardic agent acting on the If channels of sinoatrial nodal cells to decrease the rate of diastolic depolarization and thus heart rate. The benefit of ivabradine over other negatively chronotropic agents is its absence of negative inotropy. Effective management of coronary artery disease, in terms of reducing morbidity and mortality, is reliant on controlling heart rate. Ivabradine has been shown to safely and effectively reduce heart rate without compromising cardiac function in patients with coronary artery disease and more recently in patients with heart failure and raised heart rate. Furthermore, ivabradine has been shown to have a favourable side-effect profile compared with alternative bradycardic agents. This article reviews the evidence for ivabradine in coronary artery disease and heart failure and compares its safety with alternative bradycardic agents for these conditions
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available